TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01730989

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Estromineral Serena Plus
Study: NCT00743119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Dronabinol
Description: Dronabinol 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low THC marijuana
Description: marijuana cigarettes (1.98% THC) provided by NIDA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC marijuana
Description: Marijuana cigarettes (3.56% THC) provided by NIDA
Study: NCT02825472

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: 3 times per week 30 minutes of exercise training in the target heart rate zone
Study: NCT02516878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated.
Study: NCT02488707

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic intersphincteric resection (LISR group)
Description: the patient undergo laparoscopic mesorectal excision with high inferior mesenteric vein ligation combined with transanal distal resection of the rectum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal minimally invasive Total mesorectal excision (TAMIS group)
Description: Transanal minimally invasive total mesorectal excision assisted with minilaparoscopy to ligate the inferior mesenteric vessels and splenic flexure mobilization.
Study: NCT04556838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVN001 Ophthalmic Solution 1%
Description: VVN001 Ophthalmic Solution 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVN001 Ophthalmic Solution 5%
Description: VVN001 Ophthalmic Solution 5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: VVN001 Ophthalmic Solution Vehicle
Study: NCT03853213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification Training
Description: In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The letter appears in the neutral location on 90.6% of trials, thereby reinforcing participants' attending away from threat. In task 2, participants view a word or phrase corresponding to a threatening (e.g., dying) or benign (e.g., sleep) interpretation of a sentence (e.g., You have been waking up tired recently). They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback (Correct) is given for rejected threat interpretations and for benign interpretations. Otherwise, negative feedback (Incorrect) is given.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention Control Training
Description: In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The target letter is equally likely to appear in the threat location as the neutral location. Thus, participants' patterns of attention are not trained toward or away from threat. In task 2, participants view a word or short phrase corresponding to either a threatening or benign interpretation of a sentence that follows it. They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback and negative feedback are equally likely to be given regardless of whether participants endorse the threatening or benign interpretations.
Study: NCT00995930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: ACZ885 150 mg was administered subcutaneously once a month for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
Study: NCT03516838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTIVA™ BioACTIVE
Description: Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compomer
Description: Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
Study: NCT04380701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162a1
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162c2
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162c2
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study: NCT00763269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan, Silicon dioxide, fluoride
Description: Brush twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan, fluoride
Description: Brush twice daily
Study: NCT02999919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: 12.5 mg hyperbaric bupivacaine intrathecally following a successful dural puncture performed with a 27G Quincke spinal needle at the L3-4 or L4-5 intervertebral space in the sitting position
Study: NCT01367262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Description: Administered orally
Study: NCT01146431

Intervention type: DRUG
Intervention: Inhaled anesthetics
Description: Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).

Intervention type: DRUG
Intervention: Inhaled anesthetics
Description: Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
Study: NCT04266119

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online HOPE intervention
Description: Online HOPE intervention to increase mental health literacy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online HOPE intervention
Description: Online HOPE intervention to increase mental health literacy
Study: NCT03432026

Intervention type: DEVICE
Intervention: High resolution computed tomography scan of the chest.
Description: High resolution computed tomography scan of the chest \& pulmonary function tests will be done for every patient to classify them.
Study: NCT02869828

Intervention type: DEVICE
Group type: OTHER
Intervention: Monitoring by arterial catheter and Spot-on

Intervention type: DEVICE
Group type: OTHER
Intervention: Monitoring by oesophagal probe and Spot-on
Study: NCT04007588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: BMS-986205 is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. BMS-986205 work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
Study: NCT01468168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-101 Ophthalmic Suspension
Description: Ophthalmic suspension; QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-101 Ophthalmic Suspension
Description: Ophthalmic suspension; QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DE-101 Ophthalmic Suspension Vehicle
Description: Ophthalmic suspension vehicle; QID
Study: NCT01128153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5 mg tablet once daily for 24 weeks to be taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet once daily for 24 weeks to be taken orally
Study: NCT00148694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenously once every three weeks for a total of 12 weeks
Study: NCT04056299

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AR201 powder
Description: AR201 powder (Hen Egg allergen formulation) provided in capsules

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Placebo powder provided in capsules
Study: NCT03207529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study: NCT00645398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Study: NCT05229679

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV testing
Description: All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.
Study: NCT03328897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: injection of 150mg or 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: injection of 150mg or 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo
Study: NCT02256501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mono Nuclear Cell (MNC) transplantation
Description: Intracoronary administration of autologous bone marrow derived mononuclear cells
Study: NCT05413187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Grade Cannabis oil
Description: MGC, 30% CBD and 1.5% Δ9-THC
Study: NCT01372254

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAD-AS
Description: The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: 8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level. Participants in both intervention arms will receive transdermal nicotine patch.
Study: NCT01730989

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Estromineral
Study: NCT04217096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Description: Patients receive paclitaxel liposome 175 mg/m\^2 (iv, 3h) on day 1 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Patients receive S-1 at a dose according to the body surface area（\<1.25m\^2，40mg Bid；1.25\~1.5m\^2,50mg Bid；\>1.50m\^2,60mg Bid）on days 1-14 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study: NCT01022476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir potassium
Description: one pill of raltegravir 400 mg twice a day
Study: NCT01595880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin and metformin HCl extended release
Description: Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg, for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin/metformin HCl extended release
Description: Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
Study: NCT04004442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab: 800 mg IV every two weeks (on days 1 and 15 of a 28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500: 10mg/kg IV every 2 weeks (on days 1 and 15 of a 28-day cycle) Potential dose reduction: AVB-S6-500: 5mg/kg IV weekly (on days 1, 8, 15 and 22 of a 28-day cycle)
Study: NCT02179762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate exercise intervention
Description: Perform moderate exercise therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vigorous exercise intervention - standard
Description: Perform HIIT exercise therapy on a standard stationary bike

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01372254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine Patch
Description: 8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level. Participants in both intervention arms will receive transdermal nicotine patch.
Study: NCT00068406

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Study: NCT02319954

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct compression
Description: Direct compression by the surgeon with their hands on the nasal sidewall
Study: NCT03690726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation of the leg motor cortex, in combination with resistance training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Imitated magnetic stimulation: An active coil will be activated under the subject's head, firing down into the mattress, while an inactive coil will be held over the scalp
Study: NCT04959565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional behavioral intervention
Description: The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks. Every other week for 16 weeks (8 sessions in total) participants will be offered individual nutrition counselling (one intervention group) by highly experienced sports nutritionists in each country, based on Motivational Interviewing, the individual's environmental and biological prerequisites, and the Transtheoretical Model, focusing on the individual's readiness to act on a new healthier behavior

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional behavioral intervention
Description: The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks.